If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 8.3 - ALLERGAN PLC

4 Nov 2015 15:17

RNS Number : 5872E
FIL Limited
04 November 2015
Β 

ο»Ώ

Β 

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,TAKEOVER RULES, 2007 (AS AMENDED)

Β 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIESREPRESENTING 1% OR MORE

Β 

1. KEY INFORMATION

Β 

Name of person dealing (Note 1)

FMR LLC and/or one or more of its direct or indirect subsidiaries

And

FIL Limited and/or one or more of its direct and indirect subsidiaries

Β 

Company dealt in

ALLERGAN PLC

Class of relevant security to which the dealings being disclosed relate (Note 2)

Ordinary Shares and preferred convertible stock

Date of dealing

03-November-15

Β 

2. INTERESTS AND SHORT POSITIONS

Β 

(a) Interests and short positions (following dealing) in the class of relevant securitydealt in (Note 3)

Β 

Ordinary Shares

Β 

Long

Short

Β 

Β 

Number (%)

Number (%)

(1) Relevant securities

Β 

16,578,122 4.20%

(2) Derivatives (other than options)

Β 

(3) Options and agreements to purchase/sell

Β 

Total

Β 

16,578,122 4.20%

Β 

Β 

Preferred Convertible Stock

Β 

Long

Short

Β 

Β 

Number (%)

Number (%)

(1) Relevant securities

Β 

253,380 5.00%

(2) Derivatives (other than options)

Β 

(3) Options and agreements to purchase/sell

Β 

Total

Β 

253,380 5.00%

Β 

(b) Interests and short positions in relevant securities of the company, other than theclass dealt in (Note 3)

Β 

Class of relevant security:

Β 

Long

Short

Β 

Β 

Number (%)

Number (%)

(1) Relevant securities

Β 

(2) Derivatives (other than options)

Β 

(3) Options and agreements to purchase/sell

Total

Β 

Β 

3. DEALINGS (Note 4)

Β 

(a) Purchases and sales

Β 

Purchase/sale

Β 

Number of securities

Price per unit

Sale

1,740

313.0548 USD/ Share

Sale

700

313.1414 USD/ Share

Sale

300

313.07 USD/ Share

Sale

300

313.105 USD/ Share

Sale

760

313.0468 USD/ Share

Sale

1,200

313.2658 USD/ Share

Sale

700

307.67 USD/ Share

Sale

1,000

315.00 USD/ Share

Sale

2,500

315.043 USD/ Share

Buy

1,000

315.00 USD/ Share

Buy

555

311.28 USD/ Share

Buy

44

313.86 USD/ Share

Buy

6

314.96 USD/ Share

Buy

1

312.01 USD/ Share

Sale

60

311.96 USD/ Share

Sale

17

313.76 USD/ Share

Sale

13

313.13 USD/ Share

Buy (preferred convertible stock 2.8345 conversion factor)

535

1,063.1538 USD/ Share

Β 

(b) Derivatives transactions (other than options transactions)

Β 

Product name,

e.g. CFD

Nature of transaction (Note 6)

Number of securities (Note 7)

Price per unit (Note 5)

Β 

Β 

Β 

Β 

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Β 

Product name,

e.g. call option

Β 

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise

price

Type, e.g. American, European etc.

Expiry

date

Option money

paid/received per unit (Note 5)

Β 

Β 

(ii) Exercising

Β 

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 5)

Β 

Β 

Β 

Β 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Β 

Nature of transaction (Note 8)

Β 

Details

Price per unit (if applicable) (Note 5)

Β 

Β 

Β 

Β 

4. OTHER INFORMATION

Β 

Agreements, arrangements or understandings relating to options or derivatives

Β 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Β 

Β 

Is a Supplemental Form 8 attached? (Note 9) No

Β 

Β 

Date of disclosure

04-November-15

Contact name

Sally-Ann Hatton

Telephone number

01737 837148

If a connected EFM, name of offeree/offeror with which connected

N/A

If a connected EFM, state nature of connection (Note 10)

N/A

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ISELLFLELFLSIIE
Date   Source Headline
2nd Nov 20153:32 pmRNSForm 8.3 - Pfizer Inc
2nd Nov 20153:31 pmRNSForm 8.3 - Pfizer Inc
2nd Nov 20153:30 pmRNSForm 8.3 - Pfizer Inc
2nd Nov 20153:24 pmRNSForm 8.3 - Pfizer Inc Amendment
2nd Nov 20153:24 pmBUSForm 8.3 - Pfizer Inc.
2nd Nov 20153:22 pmRNSForm 8.3 - [PFIZER INC]
2nd Nov 20153:20 pmRNSForm 8.3 - Pfizer Inc
2nd Nov 20153:16 pmRNSForm 8.3 - ALLERGAN PLC
2nd Nov 20153:15 pmRNSForm 8.3 - PFIZER INC
2nd Nov 20153:15 pmRNSForm 8.3 - PFIZER INC
2nd Nov 20153:07 pmRNSForm 8.3 - ALLERGAN PLC
2nd Nov 20152:54 pmRNSForm 8.1 - [Pfizer inc]
2nd Nov 20152:11 pmRNSForm 38.5b
2nd Nov 20152:08 pmRNSForm 38.5b
2nd Nov 20152:06 pmRNSForm 38.5a
2nd Nov 201512:05 pmRNSForm 38.5(b) - Pfizer Inc.
2nd Nov 201511:55 amRNSForm 8.3 - Pfizer Inc.
2nd Nov 201511:46 amRNSForm 8.1(a) -Pfizer Inc
2nd Nov 201511:37 amRNSForm 38.5(a) - Pfizer Inc.
2nd Nov 201511:33 amRNSRule 38.5 - Pfizer INC
2nd Nov 201511:32 amRNSRule 38.5 - Pfizer INC
30th Oct 20155:30 pmRNSForm 8.3 - Pfizer Inc
30th Oct 20154:22 pmRNSForm 8.3 - Allergan plc
30th Oct 20154:06 pmRNSForm 38.5a
30th Oct 20153:59 pmRNSForm 8.1 - [Pfizer Inc]
30th Oct 20153:48 pmRNSForm 8.3 - PFIZER INC.
30th Oct 20153:37 pmRNSForm 8.3 - Pfizer Inc
30th Oct 20153:36 pmRNSForm 8.3 - Pfizer Inc
30th Oct 20153:28 pmBUSForm 8.3 - Pfizer Inc.
30th Oct 20153:27 pmRNSForm 8.1 - [Pfizer Inc]
30th Oct 20153:24 pmRNSForm 38.5b
30th Oct 20152:12 pmRNSForm 8.3 - [PFIZER INC]
30th Oct 20151:40 pmRNSForm 8.3 - Pfizer Inc.
30th Oct 20151:11 pmRNSForm 38.5b
30th Oct 201512:06 pmRNSForm 38.5(b) - Pfizer Inc.
30th Oct 201512:04 pmRNSForm 8.1(a) - Pfizer Inc
30th Oct 201511:58 amRNSForm 38.5(b) - Pfizer Inc.
30th Oct 201511:58 amRNSRule 38.5 - Pfizer INC
30th Oct 201511:57 amRNSRule 38.5 - Pfizer INC
30th Oct 201511:55 amRNSForm 8.3 - Pfizer Inc.
30th Oct 201511:54 amRNSRule 38.5 - Pfizer INC
30th Oct 201511:52 amRNSForm 38.5(a) Pfizer Inc
29th May 201411:35 amRNSForm 8.5 (EPT/RI) Replacement Pfizer Inc
28th May 201411:51 amRNSForm 8.5 (EPT/RI) Replacement Pfizer Inc
28th May 201411:49 amRNSForm 8.5 (EPT/RI) Replacement Pfizer Inc
28th May 201411:48 amRNSForm 8.5 (EPT/RI) Replacement Pfizer Inc
27th May 20144:30 pmRNSForm 8 (DD) - Pfizer Inc.
27th May 20144:04 pmRNSForm 8.3 - AstraZeneca PLC
27th May 20144:00 pmRNSForm 8.3 - Pfizer
27th May 20143:31 pmRNSForm 8.3 - Pfizer Inc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.